This PDF is the current document as it appeared on Public Inspection on 07/07/2014 at 08:45 am.
Notice of application.
Registered bulk manufacturers of the affected basic classes and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before September 8, 2014.
Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152.End Preamble Start Supplemental Information
The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, and dispensers of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (“Deputy Assistant Administrator”) pursuant to sec. 7(g) of 28 CFR pt. 0, subpt. R, App.
In accordance with 21 CFR 1301.33(a), this is notice that on December 10, 2013, S & B Pharma, Inc., DBA Norac Pharma, 405 South Motor Avenue, Azusa, California 91702-3232, applied to be registered as a bulk manufacturer of the following basic classes of narcotic or nonnarcotic controlled substances:
|Gamma Hydroxybutyric (2010)||I|
The company plans to manufacture the listed controlled substances in bulk for use in product development and for commercial sales to its customers.Start Signature
Dated: July 1, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014-15888 Filed 7-7-14; 8:45 am]
BILLING CODE 4410-09-P